


# About Acute Coronary Syndrome (ACS)



## Acute Coronary Syndrome (ACS)

Acute Coronary Syndrome (ACS) is a common and life-threatening condition, which occurs when a coronary artery is blocked by a blood clot, reducing blood supply to the heart. This disruption of blood flow can directly cause a heart attack, or cause severe pain in the chest (unstable angina).

## Burden of ACS



## What Triggers ACS?

The essential underlying condition for ACS is the build-up of plaque in the inner walls of coronary arteries that narrows the arteries, sometimes decreasing the amount of blood flow to the heart. This process is called atherosclerosis.

There are a variety of **risk factors** for the build-up of atherosclerosis, potentially resulting in ACS, including<sup>5,6</sup>:

- ◆ Family history of heart attack or unstable angina
- ◆ High cholesterol
- ◆ High blood pressure
- ◆ Diabetes
- ◆ Smoking

## Patients Require Long-Term Protection from Recurrent ACS

Death rates and rates of major cardiovascular events remain unacceptably high for ACS patients on standard antiplatelet therapy alone after hospital discharge.

**1 in 10**



ACS patients will have another major atherothrombotic event (CV death, heart attack, stroke) within the first year following the initial event<sup>7,8</sup> and 68% - 97% of deaths related to ACS occur after hospital discharge<sup>2</sup>




**Up to 30%**

of patients who leave the hospital after an ACS event are re-admitted within six months<sup>6</sup>

## Arterial clots are formed through dual pathways: Platelet Activation and Thrombin Generation

If plaque from the wall of a coronary artery ruptures, a blood clot can form at the site of the rupture. This arterial clot is formed through a dual pathway of platelet activation and thrombin generation. If the clot is large enough to block the vessel and critically reduce blood flow, the heart muscle can be damaged<sup>9</sup>.



## ACS Treatment and Prevention

The main treatment goal for ACS patients is to prevent death, stroke or recurrent heart attack by removing an existing blood clot, and subsequently stopping the formation of new clots.

A combination of antiplatelet and anticoagulant medications that target both pathways of clot formation is commonly used in the acute treatment period after a patient first experiences a heart attack<sup>10</sup>.

Unlike acute treatment, the current standard of care for long-term secondary prevention of ACS is the dual antiplatelet therapy of aspirin plus a drug class known as P2Y12 inhibitors, of which clopidogrel is the most prescribed. Dual antiplatelet therapy has improved effectiveness over aspirin alone<sup>7</sup>, however:

**Antiplatelet therapy addresses only one source of clot formation – platelet activation, leaving patients exposed to continued risk after an ACS event<sup>11</sup>**


Since thrombin levels remain elevated long after the acute phase, secondary prevention of ACS should target **both pathways** of clot formation<sup>12</sup>.

## Complementary Mechanisms Of Action

Antiplatelets and anticoagulants have complementary mechanisms of action that together address the dual pathway of clot formation and have been shown to improve outcomes, continuing to provide more complete long-term protection than antiplatelet therapy alone<sup>10,13</sup>.

Factor Xa is a protein needed to produce thrombin, which promotes the formation of blood clots. 'Xarelto' targets and inhibits Factor Xa to prevent clot formation.

In the Phase III, pivotal ATLAS ACS 2-TIMI 51 study, 'Xarelto' 2.5 mg twice daily when combined with standard antiplatelet therapy significantly reduced the composite primary efficacy endpoint of cardiovascular death, heart attack or stroke in patients with ACS compared to those who received standard antiplatelet therapy alone, without increasing the risk of fatal intracranial haemorrhage (ICH) or fatal bleeds<sup>13</sup>.




**Latest ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation (updated August 2012) recommend that treatment with 'Xarelto' 2.5 mg twice daily be considered for patients with STEMI who are at low bleeding risk and receiving dual antiplatelet therapy – aspirin and clopidogrel<sup>14</sup>**

'Xarelto' is **the only novel oral anticoagulant** to provide **more complete protection** against long-term clot formation for patients with ACS.

# About Acute Coronary Syndrome (ACS)...



## 'Xarelto' ACS Data Publications and Regulatory Milestones



### About 'Xarelto'

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, 'Xarelto' is approved for five indications across seven distinct areas of use, consistently protecting patients across more venous and arterial thromboembolic (VAT) conditions than any other novel OAC:

 <p>The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors</p>	 <p>The treatment of deep vein thrombosis (DVT) in adults</p>	 <p>The treatment of pulmonary embolism (PE) in adults</p>	 <p>The prevention of recurrent DVT and PE in adults</p>
 <p>The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip replacement surgery</p>	 <p>The prevention of venous thromboembolism (VTE) in adult patients undergoing elective knee replacement surgery</p>	 <p>The prevention of atherothrombotic events (cardiovascular death, heart attack or stroke) after an Acute Coronary Syndrome in adult patients with elevated cardiac biomarkers when co-administered with acetylsalicylic acid (ASA) alone or with ASA plus a thienopyridine (clopidogrel or ticlopidine)</p>	

Whilst licences may differ from country to country, across all indications 'Xarelto' is approved in more than **120 countries**.

Rivaroxaban was discovered by Bayer HealthCare, and is being jointly developed with Janssen Research & Development, LLC. 'Xarelto' is marketed outside the U.S. by Bayer HealthCare and in the U.S. by Janssen Pharmaceuticals, Inc. (a Johnson & Johnson Company).

Anticoagulant medicines are potent therapies used to prevent or treat serious illnesses and potentially life threatening conditions. Before initiating therapy with anticoagulant medicines, physicians should carefully assess the benefit and risk for the individual patient.

Responsible use of 'Xarelto' is a very high priority for Bayer, and the company has developed a **Prescribers Guide** for physicians and a **'Xarelto' Patient Card** for patients to support best practice. To learn more, please visit: <https://prescribe.xarelto.com>.

To learn more about thrombosis, please visit [www.thrombosisadviser.com](http://www.thrombosisadviser.com)

To learn more about VAT, please visit [www.VATspace.com](http://www.VATspace.com)

To learn more about 'Xarelto', please visit [www.xarelto.com](http://www.xarelto.com)

### References

- 1) Grech ED & Ramsdale DR. Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction. *BMJ*. 2003;326,(7401)1259-1261 **2)** Fox KA et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). *Eur Heart J*. 2010; 31(22):2755-2764 **3)** Turpie AG. Burden of disease: medical and economic impact of acute coronary syndromes. *Am J Manag Care*. 2006;12,(16 Suppl)S430-S434 **4)** Nichols M et al. European Cardiovascular Disease Statistics 2012 edition. European Heart Network and European Society of Cardiology, September 2012 **5)** Smith SC, Jr., Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. *J Am Coll Cardiol*. 2006;47,(10)2130-2139 **6)** Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. 2002 **7)** Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med*. 2001;345,(7)494-502 **8)** Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. *N Engl J Med*. 2011; 1056, 1-11 **9)** Bassand JP, Hamm CW, Ardissino D et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. *Eur Heart J*. 2007 Jul;28(13):1598-660 **10)** Hamm CW et al. ESC Guidelines for the management of acute coronary syndromes presenting without persistent ST-segment elevation. *Eur Heart J*. 2011;32:2999-3054 **11)** Braunwald E et al. *Clin Cardiol*. 2008;(Suppl.1) 31:1-17-1-20 **12)** Merlino PA et al. *Circ*. 1994;90:61-68 **13)** Mega JL et al. ATLAS TIMI 51. *N Engl J Med*. 2012;366:9-19 **14)** Steg G, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J*. 2012. doi: 10.1093/eurheartj/ehs215. First published online: 24 Aug 2012